Antenatal magnesium sulfate and spontaneous intestinal perforation in infants less than 25 weeks gestation

Objective:Evaluate spontaneous intestinal perforation (SIP)/death among extremely low birthweight (ELBW) infants before, during and after initiation of an antenatal magnesium for neuroprotection protocol (MgPro).Study Design:We tested associations between SIP/death and magnesium exposure, gestational age (GA) and interactions with GA and magnesium exposure in a cohort of inborn ELBW infants before, during and after MgPro.Result:One hundred and fifty-five ELBW infants were included, 81 before, 23 during and 51 after MgPro. ELBW infants (78.3%) were exposed to Mg during MgPro compared with 50.6% and 60.8% before and after, respectively. Incidence of SIP on protocol was 30.4% vs 12.9% off protocol (P=0.03). GA was strongly associated with SIP (P<0.01). Antenatal Mg dose was also associated with SIP/death regardless of epoch (odds ratio 9.3 (1.04–104.6)), but increased SIP/death was limited to those <25 weeks gestation.Conclusion:Higher Mg dose was associated with higher SIP and death risk among infants with the lowest birthweights. Validation of this observation in larger populations is warranted.

[1]  T. Ashmeade,et al.  Effects of Maternal Magnesium Sulfate Administration on Intestinal Blood Flow Velocity in Preterm Neonates , 2011, Neonatology.

[2]  M. Shokry,et al.  Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns , 2010, Acta obstetricia et gynecologica Scandinavica.

[3]  N. Besalduch,et al.  Presynaptic muscarinic receptors, calcium channels, and protein kinase C modulate the functional disconnection of weak inputs at polyinnervated neonatal neuromuscular synapses , 2009, Journal of neuroscience research.

[4]  P. Gordon.  Understanding Intestinal Vulnerability to Perforation in the Extremely Low Birth Weight Infant , 2009, Pediatric Research.

[5]  L. Doyle,et al.  Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. , 2009, The Cochrane database of systematic reviews.

[6]  F. Malone,et al.  A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. , 2008, The New England journal of medicine.

[7]  B. Delaporte,et al.  Effet du sulfate de magnésium sur la mortalité et la morbidité neurologique chez le prématuré de moins de 33 semaines, avec recul à deux ans : résultats de l’essai prospectif multicentrique contre placebo PREMAG , 2008 .

[8]  S. Marret,et al.  [Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial]. , 2008, Gynecologie, obstetrique & fertilite.

[9]  K. Heyborne.  Magnesium sulfate tocolysis: time to quit. , 2007, Obstetrics and gynecology.

[10]  K. Watterberg,et al.  Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial , 2004, Pediatrics.

[11]  H. Yue,et al.  Effects of magnesium on prostacyclin synthesis and intracellular free calcium concentration in vascular cells. , 2004, Magnesium research.

[12]  P. Gordon,et al.  IGF-I Accelerates Ileal Epithelial Cell Migration in Culture and Newborn Mice and May Be a Mediator of Steroid-Induced Maturation , 2004, Pediatric Research.

[13]  L. Doyle,et al.  Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. , 2003, JAMA.

[14]  J. Dambrosia,et al.  Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. , 2003, American journal of obstetrics and gynecology.

[15]  A. Stiles,et al.  Early Postnatal Dexamethasone Diminishes Transforming Growth Factor α Localization within the Ileal Muscularis Propria of Newborn Mice and Extremely Low-birth-weight Infants , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[16]  K. Nelson,et al.  Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. , 2000, American journal of obstetrics and gynecology.

[17]  D. Schendel,et al.  Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. , 2000, American journal of epidemiology.

[18]  C. Nightingale,et al.  Magnesium Sulfate in Eclampsia and Pre-Eclampsia , 2000, Clinical pharmacokinetics.

[19]  T. O'Shea,et al.  Prenatal events and the risk of cerebral palsy in very low birth weight infants. , 1998, American journal of epidemiology.

[20]  B. Khoshnood,et al.  Is tocolytic magnesium sulphate associated with increased total paediatric mortality? , 1997, The Lancet.

[21]  J. Pinto-Martin,et al.  Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group. , 1997, Pediatrics.

[22]  C. Berg,et al.  Prenatal Magnesium Sulfate Exposure and the Risk for Cerebral Palsy or Mental Retardation Among Very Low-Birth-Weight Children Aged 3 to 5 Years , 1996 .

[23]  K. Nelson,et al.  Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? , 1995, Pediatrics.

[24]  Robert M. Kliegman,et al.  Necrotizing Enterocolitis: Treatment Based on Staging Criteria , 1986, Pediatric Clinics of North America.